MW ‐19, a dihydropyrazole derivative, induces human triple‐negative breast cancer cell apoptosis by targeting apoptosis‐related pathways
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Nanting Zou und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Apoptosis, Cell Proliferation, Mice, Inbred BALB C. Die Arbeit nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Previous studies have indicated that heterocyclic substituted dihydropyrazole derivatives, particularly MW‐19, potentially exert anticancer activity in vitro; however, the underlying mechanism remains unknown. The present study was designed to investigate the mechanisms underlying MW‐19 activity in triple‐negative breast cancer cells. A sulforhodamine B assay was performed to evaluate cell proliferation inhibition rates, and the antitumor effect of MW‐19 was evaluated in mice with HCC‐1806 xenografts. Apoptosis was analyzed by Hoechst 33342 and annexin V/propidium iodide staining. Expression of pro‐ and antiapoptotic proteins and mRNA were analyzed by western blotting and reverse transcription‐quantitative (RT‐q) PCR, respectively. We found that MW‐19 significantly inhibited HCC‐1806 cell proliferation in a dose‐ and time‐dependent manner, and significantly inhibited MDA‐MB‐231 cell migration. Importantly, oral administration of MW‐19 significantly inhibited HCC‐1806 tumor growth in BALB/c‐nu/nu mice. Moreover, MW‐19 treatment induced marked apoptosis and G2/M arrest in the sensitive cell line, HCC‐1806. RT‐qPCR analysis showed that levels of proapoptotic genes (Bax, caspase‐3, caspase‐7, and Fas) were considerably increased in the MW‐19 group relative to the control group, while those of antiapoptotic factors (Bcl‐2, C‐MYC) were dramatically decreased. Consistently, Bax, caspase‐3, and caspase‐7 were significantly induced after MW‐19 treatment, while levels of phosphorylated (p‐)AKT, p‐PI3K, p‐ERK, and the antiapoptotic protein, Bcl‐2, were clearly diminished, and the P38 MAPK signaling pathway was activated. Furthermore, P38 pharmacological inhibitors abrogated MW‐19‐induced apoptosis. Together, our findings indicate that MW‐19 exerts antitumor effects by targeting PI3K/AKT and ERK/P38 signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
- School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
- Key Laboratory of Chemistry in Ethnic Medicinal Resources, Yunnan Minzu University, Kunming, Yunnan, China.
- School of Basic Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zou, N., Wu, R., Wu, Z., Zhang, C., Zhang, H., Mo, Q., Ju, M., Shi, X., Mao, Z., & Wan, C. (2024). MW ‐19, a dihydropyrazole derivative, induces human triple‐negative breast cancer cell apoptosis by targeting apoptosis‐related pathways. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14589
Vancouver
Zou N, Wu R, Wu Z, Zhang C, Zhang H, Mo Q, et al. MW ‐19, a dihydropyrazole derivative, induces human triple‐negative breast cancer cell apoptosis by targeting apoptosis‐related pathways. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14589
BibTeX
@article{Zou2024,
author = {Zou, Nanting and Wu, Runfang and Wu, Zhao and Zhang, Chunfei and Zhang, Haohong and Mo, Qingyan and Ju, Mingqian and Shi, Xinan and Mao, Zewei and Wan, Chunping},
title = {MW ‐19, a dihydropyrazole derivative, induces human triple‐negative breast cancer cell apoptosis by targeting apoptosis‐related pathways},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14589}
}
EUVIMED